US Food and Drug Administration Review Time of Supplemental New Indication Approvals of Drugs and Biologics, 2017 to 2019

This cross-sectional study examines US Food and Drug Administration regulatory review time of supplemental new indication approvals of drugs and biologics between 2017 and 2019.

Detalles Bibliográficos
Autores principales: Dhodapkar, Meera M., Ross, Joseph S., Ramachandran, Reshma
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2023
Materias:
Research Letter
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10293905/
https://www.ncbi.nlm.nih.gov/pubmed/37358857
http://dx.doi.org/10.1001/jamanetworkopen.2023.18889
_version_ 1785063085158957056
author Dhodapkar, Meera M.
Ross, Joseph S.
Ramachandran, Reshma
author_facet Dhodapkar, Meera M.
Ross, Joseph S.
Ramachandran, Reshma
author_sort Dhodapkar, Meera M.
collection PubMed
description This cross-sectional study examines US Food and Drug Administration regulatory review time of supplemental new indication approvals of drugs and biologics between 2017 and 2019.
format Online
Article
Text
id pubmed-10293905
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher American Medical Association
record_format MEDLINE/PubMed
spelling pubmed-102939052023-06-28 US Food and Drug Administration Review Time of Supplemental New Indication Approvals of Drugs and Biologics, 2017 to 2019 Dhodapkar, Meera M. Ross, Joseph S. Ramachandran, Reshma JAMA Netw Open Research Letter This cross-sectional study examines US Food and Drug Administration regulatory review time of supplemental new indication approvals of drugs and biologics between 2017 and 2019. American Medical Association 2023-06-26 /pmc/articles/PMC10293905/ /pubmed/37358857 http://dx.doi.org/10.1001/jamanetworkopen.2023.18889 Text en Copyright 2023 Dhodapkar MM et al. JAMA Network Open. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the CC-BY License.
spellingShingle Research Letter
Dhodapkar, Meera M.
Ross, Joseph S.
Ramachandran, Reshma
US Food and Drug Administration Review Time of Supplemental New Indication Approvals of Drugs and Biologics, 2017 to 2019
title US Food and Drug Administration Review Time of Supplemental New Indication Approvals of Drugs and Biologics, 2017 to 2019
title_full US Food and Drug Administration Review Time of Supplemental New Indication Approvals of Drugs and Biologics, 2017 to 2019
title_fullStr US Food and Drug Administration Review Time of Supplemental New Indication Approvals of Drugs and Biologics, 2017 to 2019
title_full_unstemmed US Food and Drug Administration Review Time of Supplemental New Indication Approvals of Drugs and Biologics, 2017 to 2019
title_short US Food and Drug Administration Review Time of Supplemental New Indication Approvals of Drugs and Biologics, 2017 to 2019
title_sort us food and drug administration review time of supplemental new indication approvals of drugs and biologics, 2017 to 2019
topic Research Letter
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10293905/
https://www.ncbi.nlm.nih.gov/pubmed/37358857
http://dx.doi.org/10.1001/jamanetworkopen.2023.18889
work_keys_str_mv AT dhodapkarmeeram usfoodanddrugadministrationreviewtimeofsupplementalnewindicationapprovalsofdrugsandbiologics2017to2019
AT rossjosephs usfoodanddrugadministrationreviewtimeofsupplementalnewindicationapprovalsofdrugsandbiologics2017to2019
AT ramachandranreshma usfoodanddrugadministrationreviewtimeofsupplementalnewindicationapprovalsofdrugsandbiologics2017to2019

Ejemplares similares